ASHP Guidelines on Preventing Medication Errors with Chemotherapy and Biotherapy

Barry R. Goldspiel, James M. Hoffman, Niesha Griffith, Susan Goodin, Robert DeChristoforo, Capt Michael Montello, Judy L. Chase, Sylvia Bartel, Jharana Tina Patel

American Journal of Health-System Pharmacy · 2015 · 101 citations · 41 references

Concepts

Abstract

The purposes of these guidelines are to define best practices for the safe use of chemotherapy and biotherapy agents and to assist practitioners in improving their medication-use systems to prevent medication errors and patient harm from these agents. Although the guidelines are intended primarily to address use of chemotherapy and biotherapy agents in cancer treatment, some recommendations may be more broadly applicable across the medication-use system. These guidelines supplement ASHP’s Guidelines on Preventing Medication Errors in Hospitals and address error prevention within diverse healthcare settings.1 Further, these guidelines provide updated general guidance to include a standard definition of a “medication error” and applicable aspects of recommendations from the National Coordinating Council on Medication Error Reporting and Prevention (NCC MERP). NCC MERP’s definition of a medication error is: any preventable event that may cause or lead to inappropriate medication use or patient harm while the medication is in the control of the healthcare provider, patient, or consumer. Such events may be related to professional practice, healthcare products, procedures, and systems, including prescribing; order communication; product labeling, packaging, and nomenclature; compounding; dispensing; distribution; administration; education; monitoring; and use.2 For the purposes of these guidelines, chemotherapy and biotherapy agents are defined as any medication that (1) is listed in section 10:00 of the American Hospital Formulary Service3 (AHFS) pharmacologic–therapeutic classification system; (2) has at least one FDA-labeled indication to prevent or treat cancer, even if not listed in AHFS 10:00; or (3) is an investigational medication being used to prevent or treat cancer. This definition includes medications administered by any route. For simplicity, the term “chemotherapy” is used throughout these guidelines to refer to any chemotherapy or biotherapy medication that is used for cancer treatment. The variety of therapies used in the treatment of cancer will only increase as advances are made, and healthcare organizations will confront the challenge of defining the products that require special procedures for safe use. Given the complexity of cancer care, it is recommended that such a list be as inclusive as possible. While these guidelines focus on the safe use of chemotherapy in treating cancer patients, in some situations chemotherapy agents may be used for nonmalignant diseases. In general, these additional safety procedures should apply for all uses of a chemotherapy agent, regardless of indication. Although they are specific to use of chemotherapy for cancer treatment, many of the principles of these guidelines also apply to cancer supportive care (e.g., treatment for pain and nausea). Finally, for organizations that conduct clinical research, investigational chemotherapy agents should be included in all safety systems established for FDA-approved chemotherapy agents. These guidelines provide wide-ranging recommendations for preventing errors with chemotherapy agents in healthcare organizations, with an emphasis on hospitals, infusion centers, and ambulatory care clinics that offer direct pharmacy services. Nevertheless, it is strongly recommended that the guidance also be adopted by other settings, including physician office practices, home care, and patients self-administering oral and injectable therapies at home. Other guidance on the safe use of chemotherapy in the ambulatory setting has been published by the American Society of Clinical Oncology (ASCO) and the Oncology Nursing Society (ONS).4 These recommendations cover known procedural, technical, and behavioral elements that could systematically reduce a healthcare organization’s vulnerabilities to errors. Given use of an electronic medical record (EMR) increased from 3.8% of hospitals in 2007 to 8% in 2011, and computerized provider order entry (CPOE) use increased from 4% of hospitals in 2005 to 34% of hospitals in 2011,5 additional information on the unique considerations of using CPOE for chemotherapy ordering has been included in these guidelines. Strict adherence to good practice recommendations is not sufficient. Because the complexities of chemotherapy use afford unlimited opportunities for system failures, continuous diligence to verify accuracy is critical by all persons responsible for medication-use functions for chemotherapy. These guidelines focus on the medication-use responsibilities shared by and unique to specific professional healthcare disciplines, progressing from general to specific applications. The structure of the guidelines, by necessity, includes the repetition of some material, repeated and enhanced in specific sections and recommendations for different healthcare professionals. With the growth in use and number of oral chemotherapy agents on the market, a greater responsibility for care management is now placed on the patient. It is essential that applicable sections of these guidelines extend to patients so they can participate in protecting their own safety. The guidelines contain the following major sections: Recommendations for healthcare organizations, Recommendations for multidisciplinary monitoring of medication use and verification, Recommendations for prescribing systems and Recommendations for medication and systems and for Recommendations for medication systems and for Recommendations for patient Recommendations for and and Recommendations for and medication errors. Because of the complexity of and in practice and aspects of these guidelines may be more applicable to some practice and other healthcare should use their professional in and the guidance to their own These guidelines focus on safe use of a specific of medications at of the medication-use and should be as by other clinical and practice including and guidelines. Although the of medication errors for chemotherapy administered in the setting is not of the of errors with and chemotherapy in the ambulatory setting been In one the chemotherapy error errors For errors with of and errors with of Errors across all of the medication-use and ordering errors a of errors in chemotherapy in the infusion at a major cancer The error with oral chemotherapy agents is medication errors can with these therapies across all of the medication-use and a error with oral chemotherapy to patients with In the errors at the prescribing and of the of medication errors for chemotherapy the safe use of these therapies unique that additional safety agents a and they are used in and are such as and to and other clinical agents can cause at FDA-approved and with FDA-approved for safe medication including pharmacy recommended that healthcare organizations their medication-use systems to prevent medication errors with prevention a many chemotherapy agents are administered the or ambulatory care number of patients are self-administering oral chemotherapy agents at should be applicable to the diverse in chemotherapy agents are a for in medication-use systems for chemotherapy agents. of major cancer that the safety systems used for chemotherapy agents are to oral chemotherapy and that many other recommended safety practices for chemotherapy agents are not and patient care, for patients the of healthcare are to the functions throughout the medication-use of and of and for and organizations are should with from to and procedures for the medication-use and to These and procedures should include and for persons with medication-use general system that vulnerabilities to and of and with the system. Further, and errors and investigational chemotherapy agents should be in all settings, and in the procedures that patients at should be practice should and procedures that healthcare and chemotherapy and patients medications are to For and specific and or in a practice may be included in the should and practice for and of the that are essential for with chemotherapy. for and chemotherapy should include in to chemotherapy agents to and to patients and adherence with should be in and be and for and should healthcare to patient care, and safety. healthcare and chemotherapy and patients medications should be in their practice setting should include an of to all the and functions that patient and responsibilities should be and should be healthcare from different will and with to the chemotherapy medication-use Further, healthcare organizations should require that all and or and all persons may be to or in the of their and should and in and procedures for to other and the and and of should be or more if It is the responsibility of medication-use system and to the that or some healthcare from and chemotherapy participate in the chemotherapy medication-use and patients chemotherapy should be and information of the following to their of practice and on the chemotherapy used in their practice of chemotherapy and and they with the FDA-approved or or are of an investigational of including for for the of medication that can be a a of treatment, or a to use for for and the of practice setting cancer patients chemotherapy should provide opportunities for professional and related to chemotherapy of the for healthcare in should be related to chemotherapy agents and their use (e.g., and infusion to chemotherapy agents should be to related to the clinical and care of these that may with the and errors in the medication-use are or by medical should be and for use by all and chemotherapy to that all been treatment. In some may additional patient that supplement the medical For it has been the responsibility of and to medication and of medications that and for patient. Medication for cancer patients at a include the following and a unique or medical that a cancer and and that may treatment to medication including and (e.g., all and and medications used by a patient, including the it from the they and and it from the the medications and administered for patient and for any as administered (e.g., treatment as a of the treatment (e.g., and with the specific treatment of of use (e.g., number of to number of treatment or and The product product and for from that and agents and the used in that the treatment treatment The treatment or number for treatment The on a patient treatment, treatment and The of administered for medications with established (e.g., or repeated as a of Other settings, such as and care organizations are to the and errors that in These and could additional opportunities for errors of and and other are at and by more one provider or of In hospitals and systems, medical information has been a medical In in practice, home care, and care organizations on the of a medical medication and may at should be to that for a chemotherapy medications are and that medication at all in care, and that patient is of are recommended to and medical information electronic system by any one provider are to a for all healthcare and electronic an updated patient medication that patient safety and be Because patients care from more one healthcare provider, their provider, care or patient should patient care with other and systems should to a healthcare with their healthcare the medication and should be organizations should and their should and use or that are from a computerized for used chemotherapy and services. errors by treatment information in a and CPOE opportunities and other should be with from the healthcare and chemotherapy should be with the treatment and include such as for and as a of and and should include the treatment including oral medications that may be by an provider and patient should also include for to that and treatment These may also to and other for patient multidisciplinary should be in for the and of these standard order including of the is a in and from an or and to the These should include the as to to and that they are using the including for oral therapies administered by patients, and medication ordering by to only such as and unique number (e.g., medical record or of to patient and the order and are to be and defined by the for are to use to chemotherapy can be Medication medication and as a of and the and to be of the if and medication and and or number to with the should by number or the treatment that is to be For investigational chemotherapy should also include the and as for may be used to different of treatment, such as chemotherapy and investigational order many of the related to medication that are with healthcare be that errors may from that list chemotherapy medications may also to prescribing errors in can the of a should be on (e.g., can that are to and these should be Further, of these order should also be and medications on the of a of a order should be of and on the should chemotherapy ordering (e.g., to to with the clinical organizations that on should all on a defined and that only the of are and that are and CPOE should be to the safety of the CPOE an to safety the chemotherapy prescribing of CPOE for chemotherapy to other CPOE many of the safety and as such as order across chemotherapy and and of care medications and some patient CPOE also additional that are not with a system. For the to control to sections of the system can be in to may order chemotherapy or specific investigational CPOE by to be by different in different at the and it as a for the ordering provider clinical and to structure specific in and CPOE a including additional safety not with diligence by the and of the are essential using CPOE for chemotherapy. CPOE for chemotherapy be with CPOE a major in an organization’s chemotherapy use and and it may errors that may not in the In a and one be that the by CPOE not the safety of the the the of are principles of and that be such as in safety and an of should be CPOE for chemotherapy. Given the patient safety a and should be as such an has been the of a CPOE patient be to all These include provider that chemotherapy and medications and should be are and in order the are This at the the order is by the by and the of the on the patient. The number and of to verify the order should be with of the CPOE and chemotherapy a and known as to or of the chemotherapy order by an physician or other Clinical is for Clinical can the of the ordering and include specific chemotherapy considerations on patient such as and the for supportive care medications (e.g., such as and should be as and be with the for clinical The of the order a or specific of should be and to treat or treatment be for the patient to treatment. should for and to the CPOE system should be by a multidisciplinary and include provider as as from continuous monitoring of the order entry including safety and and are multidisciplinary and to include and information systems CPOE for chemotherapy is an and CPOE should be to provide guidance for ordering chemotherapy. the is the and safety can be is the and information system. CPOE and the of the CPOE should the to a specific or that the information to a and These ordering are or and they are essential to using CPOE for on the system and to order additional information (e.g., for supportive care, or may be of the order such as (e.g., or or if should be of the order to by the The system may also be to prevent ordering the of or a to specific such as prescribing order from to a CPOE system be in ordering an error may in and the of an investigational ordering should be in the of the and they should be to on the ordering they are use. The of these is not a order and investigational chemotherapy includes a of and of the to be at the to be and not with the of of the chemotherapy or biotherapy if is a in the some systems may not a or to and in to in a could chemotherapy by the CPOE system and electronic record should for an electronic and of the by the and any in the chemotherapy use in the system the or that the order is by the is should physician to or is by the is and critical using a CPOE and the for error to order the a is on a in or an investigational is the the or if is CPOE systems may be to the they the for or of error is the of some The system can the and to or use the to the an or entry can in a It is for to that could from entry errors. may be to prevent entry error by an from a entry by a or for to chemotherapy in the event the CPOE is not (e.g., system should be and the should the CPOE (e.g., CPOE as as to of and of the should be of the and for all of a CPOE system many for the care Although in a CPOE system may be for it may also reduce the of in the or while on the the for care professionals. While CPOE has been to prevent prescribing it is not a and diligence and are essential to a safe chemotherapy using some of in will in the and use of all the in a CPOE for therapies such as chemotherapy. The of CPOE on and information It is critical a in the and monitoring of for treatment, medication-use systems should not healthcare to use or to or a chemotherapy for chemotherapy or the an essential in the they are to persons medications or and by one or more It is to chemotherapy treatment as as In general, for chemotherapy may essential and are for chemotherapy medication and should be is to that safety are verification, and It is essential that patient care is not any systems should should be as a of or and that direct as a of has guidelines for chemotherapy in patients that using if the is should information on should also define for other such as in or patients, is or is not the may treatment different from In all the treatment and medication should or used in and the from should be for and (e.g., and and and in to in and For and from the that should in the treatment and medication should be established for the of an medication for and that be included on The following are for should be and ordering chemotherapy the by the should be are not they in products or a for (e.g., to and product The should be for medications should include the from are and are for or treatment and medication should the on treatment are the order is for chemotherapy as of the clinical information for the should be included in the and should be in The should be in medication and are in (e.g., (e.g., should be used for should be Medication should the and to the the and is the in and administered from a and should be standard and been The should be The should be The and the of treatment should be and medication should the repeated the on is to be within a treatment or and the of a treatment or The and is to or the in medication is to be should be is as or it may be events for should be as or or in the system. The medical record should contain a for the chemotherapy treatment (e.g., a to product labeling, the guidelines, guidelines, or an investigational information may be included in the medication order to provide additional Although healthcare used and to chemotherapy medications and treatment the practice is and should be for and for medication use should be in medication and and should not be used in for chemotherapy should be in a medication order that with these recommendations as for a patient with a of in by continuous infusion for and at on systems should include for chemotherapy should be to chemotherapy and and should be established are These should include the of a chemotherapy that may be administered as a the that may be administered a defined for administered medications and for oral and the by should be For some the of at or the of to in patients with for and may be defined by treatment and and may In the of administered in some practice may be the of within that practice should also be established for the of a chemotherapy that may be administered one treatment or the of that may be administered to a patient within or In should be established for chemotherapy medications used in specific for in clinical may be by agents with should in treatment (e.g., care treatment and on and clinical that healthcare an order for chemotherapy medications defined be For patients chemotherapy medications for been should be updated in their medical and in any should be and by healthcare for chemotherapy In care the medication-use system should include a multidisciplinary that related to medication-use The should and and procedures for related to patient treatment medications should be and administered if a be and are to be should all responsibilities in the medication-use in the patients investigational at in clinical be to that the safety and that are used for FDA-approved chemotherapy therapies apply to and oral and investigational medications and monitoring patients should that is to an investigational and should be in the of clinical the use of and investigational chemotherapy that chemotherapy are in a to and investigational medications are and administered in with and and should be on and that the and treatment of patients chemotherapy medications and investigational therapies (e.g., Because a and the for use in clinical an of the should be for at all medications are and should be are and information should be by persons with the investigational (e.g., an investigational is to be at more one within a procedures should be to that information is at all patients for healthcare with information and should also be should be established all in the medication-use for investigational of chemotherapy the is for treatment Given the with (e.g., is specific considerations apply to of should be to with to chemotherapy. should that the chemotherapy is only intended for including contain to that will be administered should be placed in from medications administered by other (e.g., in the to the medications should be from medications with other of chemotherapy should so in a setting that has been for that by should be to is an essential that the accuracy and of medical treatment. It is that healthcare any related to medication treatment should that and other system of information patients and their medications has been as the cause of medication In order to verify for all persons and chemotherapy medications and patients should also to of treatment and including home medication information and should be to all persons provide patient healthcare provider has a responsibility to information with other and to patient safety and an treatment that treatment should responsible and and pharmacy and other persons are responsible for and medication should and and chemotherapy medications should at defined in the chemotherapy use systems may computerized safety should also include computerized systems (e.g., are used to and verify and the and of for chemotherapy and to medication for with In to can also as a on to medication a computerized or system should a a all and product a product is In situations in a is not a or may as the medications to patients includes and The system has established to that an chemotherapy is and administered to the patient for it intended should so that responsibility for or own system. These established a chemotherapy medication is and and chemotherapy should be with the treatment should order all the medications for the treatment including and supportive care at the and to of any of the prescribing chemotherapy on a on and in patient should be to be the information is In order may assist in all of a treatment at the all treatment in that can be for and accuracy and with treatment. should chemotherapy may be by (e.g., medical and healthcare with prescribing (e.g., physician the by these these should be by at least one responsible other the is medical for chemotherapy be by a responsible the the medication should order for a chemotherapy treatment. This is The should be with and that the treatment (e.g., a published standard investigational the patient is in an investigational of the and of should be persons a order for chemotherapy medications to the medication and verify published (e.g., product labeling, published in professional treatment standard and on The and the should be at Because information in published for chemotherapy medications should be the in the specific treatment (e.g., published a is not the treatment should be with a that been as the treatment and or at least including and and be a that by all and (e.g., National should be and be for In order should be updated as as for or Although order and CPOE the of and all medication should be for with the repeated from by following these The a patient and the treatment should be to that an has treatment from a medication and are should be (e.g., should and procedures (e.g., should be It is to in and as a to errors in and should be and treatment should be to they are within or if treatment are and and or medication should be for with chemotherapy treatment. For patients treatment in clinical in more one or are (e.g., and treatment and and should be with at least one with the clinical other the (e.g., the an or a or The should be treatment not or for and number of and and should be that and supportive medications that chemotherapy and by been and are and (e.g., and growth their should be and medications and treatment should be to the and medication treatment been all related to and accuracy should be in a on or to as or or and the products for patient and the persons and the Although and may and may be as a continuous in product on or as a record for patient, all should the used in the should also special and such as the indication of special product for the for special and and should be to the product and should be by a a The on should be by a care provider not the should include the for and accuracy of with to special or that the elements in chemotherapy may be a can as a if practitioners procedures in using and products should be the and the order by an not in the may also be for persons medications to patients or for use to verify a a medication is their medications or should the their and with information they from their healthcare (e.g., a chemotherapy treatment, chemotherapy medication should be the by at least are and to chemotherapy and should be This includes any infusion settings, should be at the of of the throughout the and a care for the patient. should that the medication will be administered to the intended patient by a and unique or number with medication (e.g., or and that a (e.g., additional and of and are healthcare should the medication and the general is chemotherapy products and product should be patients their medications it from should the to the and for use of to with or they a patients should be to their treatment and and medication with information they the treatment. using should to chemotherapy should be In ambulatory care practice, it is for patients to chemotherapy medications in a setting a physician and a other healthcare all related to and monitoring treatment a these the care should and be in the The chemotherapy medications should from agents are to so it is to medication errors from at one of the a care a error if they are the and are for or For all chemotherapy agents administered at a healthcare the clinical should be on of chemotherapy should be and a for should be For oral chemotherapy that patients to their chemotherapy should be and at patient for adherence should be at should be to and and prescribing is by medical that and with FDA-approved product uses on information from and care in information and for chemotherapy medications with other healthcare should require for all chemotherapy medications and other by or to be by a physician with in the to errors in and care for prescribing chemotherapy should an to and procedures related to prescribing chemotherapy they are to order for patient should and for chemotherapy may be for patients with the following (1) that a patient to from treatment with (e.g., or in patients with or agents in patients with (2) a of or chemotherapy (3) that patients to (e.g., or or and patients on medications with a for a with a chemotherapy. should also for their guidelines for prescribing that are administered with chemotherapy guidelines for supportive care a

References

41